Verastem, Inc. (VSTM) stock forecast & analysis
7.70
NasdaqCM · USD
Down: -0.20, -2.5%
7.80Up: +0.10, +1.3%
1 analysis
- Open
- 7.95
- Previous close
- 7.90
- Day range
- 7.52 – 8.02
- 52-week range
- 3.43 – 10.82
- Volume (shares)
- 4.07M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 90.56M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.32
- Market cap
- 697.34M
Market Scanner’s AI analysis of Verastem, Inc. (VSTM), updated October 2026: Verastem Oncology's (VSTM) substantial revenue growth and ovarian cancer study data contrasted with ongoing profitability concerns and mixed technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Verastem, Inc. (VSTM) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Verastem Oncology's (VSTM) substantial revenue growth and ovarian cancer study data contrasted with ongoing profitability concerns and mixed technical indicators.
Recent analyses for Verastem Oncology (VSTM) covered significant year-over-year quarterly revenue growth, driven by a substantial increase in total revenue. The company also presented updated data from its RAMP 201 study for ovarian cancer and provided an update on its KRAS G12D program. However, profitability metrics such as net profit margin and return on equity remained negative, and market technicals showed mixed signals with some short-term downward momentum and weakening bullish indicators.
VSTM news & sentiment
News reports highlighted Verastem Oncology's presentation of updated ovarian cancer study data and progress on its KRAS G12D program, noting the significant market potential for KRAS inhibitors. Social media discussions were not covered in the provided notes.
VSTM technical picture
The price was trading above its 50-day and 200-day Simple Moving Averages, suggesting a positive medium and long-term trend. Short-term momentum showed some downward pressure, while momentum indicators like RSI sat in neutral territory and MACD suggested weakening bullishness. The stock traded within its Bollinger Bands, with some selling pressure indicated by the Money Flow Index.
Fundamentals
Verastem Oncology (VSTM) reported substantial year-over-year and sequential quarterly revenue growth. However, the company's profitability metrics, including net profit margin and return on equity, remained significantly negative.
Factors discussed — upside
- Substantial year-over-year quarterly revenue growth of 1775.4%
- Sequential quarterly revenue increase from Q1 2026 to Q2 2026
- Updated data presented from RAMP 201 study for recurrent low-grade serous ovarian cancer
- Update provided on KRAS G12D program
- Current price above 50-day and 200-day Simple Moving Averages
Factors discussed — risks
- TTM net profit margin of -231.6%
- TTM operating margin of -182.6%
- TTM Return on Equity of -471.2%
- 10-day Exponential Moving Average above current price
- Money Flow Index below 50, suggesting selling pressure
- Revenue Growth
- Profitability
- Clinical Study Data
- Market Technicals
Summary updated .
VSTM technical indicators
Common technical indicators for VSTM, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 7.17 | Price above |
| 10-day exponential moving average | 7.84 | Price below |
| Relative strength index (14-day) | 51.91 | Neutral |
| MACD line (12/26/9) | 0.2008 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 7.18 – 8.39 | Price inside the bands |
Analyses
Recent VSTM.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Verastem, Inc.?
- Verastem Oncology (VSTM) has demonstrated substantial revenue growth, highlighted by a significant year-over-year increase and sequential quarterly gains. The company has also presented updated clinical data from its RAMP 201 study for ovarian cancer and provided an update on its KRAS G12D program, with current market technicals showing the price above key moving averages.
- What are the risks for Verastem, Inc.?
- Profitability remains a concern for Verastem Oncology (VSTM), with negative net profit, operating, and return on equity margins. Market technicals also indicate some short-term downward momentum and weakening bullish indicators, alongside selling pressure suggested by the Money Flow Index.
- Is Verastem, Inc. bullish or bearish?
- Recent AI analyses of Verastem, Inc. examined factors on both sides. Discussed upside: Verastem Oncology (VSTM) has demonstrated substantial revenue growth, highlighted by a significant year-over-year increase and sequential quarterly gains. The company has also presented updated clinical data from its RAMP 201 study for ovarian cancer and provided an update on its KRAS G12D program, with current market technicals showing the price above key moving averages. Discussed risks: Profitability remains a concern for Verastem Oncology (VSTM), with negative net profit, operating, and return on equity margins. Market technicals also indicate some short-term downward momentum and weakening bullish indicators, alongside selling pressure suggested by the Money Flow Index. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Verastem, Inc.?
- News reports highlighted Verastem Oncology's presentation of updated ovarian cancer study data and progress on its KRAS G12D program, noting the significant market potential for KRAS inhibitors. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Verastem, Inc.?
- Every analysis of Verastem, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh VSTM.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.